These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38076362)

  • 21. [Clinical efficacy analysis of TMF for the treatment of hyperviremia HBeAg-positive chronic hepatitis B patients with incomplete response to first-line oral antiviral nucleos(t)ide analogues].
    Sheng QJ; Han C; Li YW; Zhang C; Dou XG; Ding Y
    Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):252-257. PubMed ID: 37137850
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    Berg T; Simon KG; Mauss S; Schott E; Heyne R; Klass DM; Eisenbach C; Welzel TM; Zachoval R; Felten G; Schulze-Zur-Wiesch J; Cornberg M; Op den Brouw ML; Jump B; Reiser H; Gallo L; Warger T; Petersen J;
    J Hepatol; 2017 Nov; 67(5):918-924. PubMed ID: 28736139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
    Buster EH; Flink HJ; Simsek H; Heathcote EJ; Sharmila S; Kitis GE; Gerken G; Buti M; de Vries RA; Verhey E; Hansen BE; Janssen HL
    Am J Gastroenterol; 2009 Oct; 104(10):2449-57. PubMed ID: 19584831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Viganò M; Invernizzi F; Lampertico P
    Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HBsAg Quantification in Clinical Practice.
    Seth AK
    J Clin Exp Hepatol; 2012 Mar; 2(1):75-80. PubMed ID: 25755408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients.
    Xun Z; Liu C; Yu QQ; Lin JP; Huang JL; Yang TW; Wu WN; Wu SH; Ou QS
    Clin Chim Acta; 2020 Mar; 502():120-127. PubMed ID: 31891671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.
    Xue Y; Zhang M; Li T; Liu F; Zhang LX; Fan XP; Yang BH; Wang L
    World J Gastroenterol; 2021 Apr; 27(14):1497-1506. PubMed ID: 33911470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
    Chen CH; Hsu YC; Lu SN; Hung CH; Wang JH; Lee CM; Hu TH
    J Viral Hepat; 2018 May; 25(5):590-597. PubMed ID: 29274189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
    Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Trend in Antiviral Therapy for Chronic Hepatitis B.
    Chien RN; Liaw YF
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35216027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.
    Chi H; Hansen BE; Yim C; Arends P; Abu-Amara M; van der Eijk AA; Feld JJ; de Knegt RJ; Wong DK; Janssen HL
    Aliment Pharmacol Ther; 2015 May; 41(9):867-76. PubMed ID: 25752878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-α therapy.
    Luo H; Tan G; Hu X; Li Y; Lei D; Zeng Y; Qin B
    Virol J; 2023 Jul; 20(1):161. PubMed ID: 37475028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase.
    Zhao Q; Liu K; Zhu X; Yan L; Ding Y; Xu Y; Lou S; Zhao G; Xie Q; Gao Y; Bao S; Wang H
    Antiviral Res; 2020 Dec; 184():104953. PubMed ID: 33065138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection.
    Choi HSJ; van Campenhout MJH; van Vuuren AJ; Krassenburg LAP; Sonneveld MJ; de Knegt RJ; Hansen BE; Janssen HLA
    Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1933-1940.e1. PubMed ID: 32890755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
    Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
    Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-interferon treatment in hepatitis B.
    Woo ASJ; Kwok R; Ahmed T
    Ann Transl Med; 2017 Apr; 5(7):159. PubMed ID: 28480195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment.
    Mimura S; Fujita K; Takuma K; Nakahara M; Oura K; Tadokoro T; Tani J; Morishita A; Ono M; Himoto T; Masaki T
    Exp Ther Med; 2023 Dec; 26(6):587. PubMed ID: 38023352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.